Despite these statistics , a
surprisingly few number of "Cough Centers" exist nationally.

(Nasdaq:MTXX) will be presenting on February 22, 2005, at the Roth
Capital Partners 17th Annual Growth Stock Conference at the St.matrixxinc. Please note that this conference is by
invitation only.
Matrixx Initiatives , Inc.

remedy breathe

m.zicam. For additional
information, contact William Hemelt, chief financial officer,
602 -385-8888, whemelt@matrixxinc.1 million compared to $940,000 in 2003.

airway somni

During the
presentation the Company will outline expectations for 2005.matrixxinc.

Matrixx Initiatives, Inc.com.
For more information about the conference visit:
http://www. 2004 Full Year Sales Reached $60.7 million , or $0.11 per share, in 2003. Net income for 2004 was
approximately $5. Additionally, Zicam(R)
branded products' growth at retail continues to outpace the cough and cold
category. According to the market research,
awareness of the brand is below 15% and trial levels are below that. During the year
we increased our total cash position by $7 million (including $5 million
restricted for a self structured insurance program). We expect the current level of
legal expense to continue throughout 2005. 24th Street, Suite 455, Phoenix,
Arizona 85016.

mouthpiece relieves

Johnson also said, "Recently, the Company finalized its 2005 business
plan. The Company also manufactures and
markets a full line of Zicam brand pharmaceuticals, including Zicam Cold
Remedy Chewables(TM); Zicam Cold Remedy Oral Mist(TM); Zicam Cold Remedy
RapidMelts(TM); Zicam Allergy Relief; Zicam Cold Remedy Swabs(TM); Zicam Kids
Size Cold Remedy Swabs(TM); Zicam Extreme Congestion Relief; Zicam Sinus
Relief; and Zicam Nasal Moisturizer .com,
480-675-0400.

breathe shrink

24th Street, Suite 455, Phoenix, Arizona 85016.2 million, a
38% increase above 2003 net sales of $43. We surpassed our stated goals of revenue and
income growth of 30% for the year.4 9.

Matrixx Initiatives, Inc.

snorers shrink

Additionally, in July 2004 Matrixx began
distributing six new Cough Mist(TM) products for the 2004-2005
cough/cold season. A concentrated, two-day program will
allow institutional investors to meet the executives from a select
group of companies that have been hand picked by the Roth Capital
Partners research team. This closely mirrors the average and median market cap for
the proposed Russell Microcap(TM) Index which is expected to be around
$277 million and $176 million, respectively.0 million, or $0. For additional information, contact William
Hemelt, chief financial officer, 602-385-8888, whemelt@matrixxinc.

shrink unobstructed

Roach. Osteoporosis is also a focus due to its high
incidence in patients with lung disease.com.17 per share, compared to net income
of $1.35 per share.
These forward-looking statements are based on the Company's current
expectations and are subject to a number of risks and uncertainties, many of
which cannot be predicted or quantified and are beyond the Company's control.

tissues unobstructed

"Our physicians are specialty trained to seek out the root causes of
chronic coughs, and we've equipped them with the diagnostic and therapeutic
equipment to perform all of the necessary tests here in the office," said Dr. is a rapidly growing innovator in the
development, manufacture and marketing of over-the-counter (OTC )
pharmaceuticals, which utilize innovative drug delivery systems.
Carl Johnson, President and Chief Executive Officer, said, "2004 was
another record year for Matrixx. The Company has grown from
marketing only 2 Zicam(R) products in the beginning of 2002, to marketing
16 Zicam products at the end of 2004. However,
among users of our products, consumer satisfaction is high with approximately
70% of people who try the product expressing their intention to purchase the
brand in the future .35
Average Shares
Outstanding (mil) 9. In studies published in the October 2000 issue of ENT --
Ear, Nose and Throat Journal, and separately in the January 2003 issue of QJM:
An International Journal of Medicine, the Zicam Cold Remedy product was shown
to reduce the duration of the common cold.com.

unobstructed airways

com.
To register for this conference, please contact your Roth sales
representative at 800-678-9147.
For the fourth quarter ended December 31, 2004, the Company reported net
sales of $27. For the 52 weeks ended December 26, 2004, retail sales
(three-outlet syndicated scanner data; not including our customer Wal-Mart) of
Zicam products increased approximately 25%, while the total cough/cold
category was down approximately 5% compared to the prior year. We anticipate
the increased investment in R+D and marketing, along with the continued high
level of expected legal expenses, may slow the rate of net income growth
compared to that achieved in recent years. During 2004 legal expense increased to
$5. 31, 2003 Dec. Zicam, LLC, its wholly-owned subsidiary, produces ,
markets and sells Zicam(R) Cold Remedy nasal gel, a patented, homeopathic
remedy that has been clinically proven to reduce the duration and severity of
the common cold.com.

Sites offering online shopping for products and services related to snoring.

airways tissues

In studies published in the October 2000 issue of ENT --
Ear, Nose and Throat Journal, and separately in the January 2003 issue
of QJM: An International Journal of Medicine, the Zicam Cold Remedy
product was shown to reduce the duration of the common cold.com.
(Nasdaq: MTXX), a rapidly growing innovator in the development and marketing
of branded over-the-counter pharmaceuticals, today announced financial results
for the fourth quarter and the year ended December 31, 2004."

Fourth Quarter and Year-end 2004 Consolidated Financial Results

2004 2003
($000s) 4th Qtr 4th Qtr 2004 2003

Net Sales $27,001 $18,226 $60,231 $43,496
Cost of Sales 7,999 5,445 18,405 13,455
Gross Profit 19,002 12,781 41,826 30,041
Operating Expenses 15,544 10,022 31,862 21,642
Research and Development 541 855 1,887 2,557
Income from Operations 2,917 1,904 8,077 5,842
Total Other Income
(expense) 6 6 330 (71)
Net Income Before Tax 2,923 1,910 8,407 5,771
Income Tax Expense 1,250 879 3,450 2,427
Net Income $1,673 $1,031 $4,957 $3,344

Net Income per
Diluted Share $0. For more information regarding Matrixx products, go to http: //www.
To find out more about Matrixx Initiatives, Inc (Nasdaq: MTXX), visit our
website at http: //www. Matrixx is located at 4742 N.

collar intra

"

The Institute for Better Breathing is a group pulmonary practice that, in
addition to chronic cough, also specializes in asthma, sleep diseases, nasal
congestion , and snoring. The
Company also manufactures and markets a full line of Zicam(R) brand
pharmaceuticals , including Zicam Cold Remedy Chewables(TM); Zicam Cold
Remedy Oral Mist(TM); and Zicam Cold Remedy RapidMelts(TM); Zicam
Allergy Relief; Zicam Cold Remedy Swabs(TM); Zicam Kids Size Cold
Remedy Swabs(TM); Zicam Extreme Congestion Relief; Zicam Sinus Relief;
and Zicam Nasal Moisturizer. To find out more about Matrixx Initiatives, Inc. Matrixx is located
at 4742 N.rothcp.6 9.5

Selected Balance Sheet Information

($000s) Dec .com or
Institutional Investors, Max Ramras at The RCG Group, max@thercggroup. Forward-Looking Statement Disclaimer:
This news release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995.

mouthpiece somni

Combined, these conditions kill over 100,000 Americans
each year, making it the fourth leading cause of death in the United States
and the second leading cause of disability.

About Matrixx Initiatives, Inc.
For the full year 2004, the Company reported net sales of $60."
Additionally, Zicam is an emerging brand and we believe significant growth
opportunity continues to exist, as evidenced by market research conducted
among over 500 adults in the past year.

nasal swollen

The new "Cough Center" at the IBB provides
diagnosis and treatment for all causes of chronic cough.
(Nasdaq:MTXX), visit our website at www. 40% of this year's participating companies are
presenting here for the first time. Net income for the fourth quarter of 2004 increased
62% to approximately $1.
The results we have achieved over the past year are particularly
gratifying given the challenges presented by the unsubstantiated claims
against one of our products . We plan several product improvements and new product
introductions for 2005 and we expect to introduce a new brand.11 $0.

eez breathe

Over the past four years, the Company has
had a compound annual growth rate of over 53% which places Matrixx's revenue
growth in the top 10% of Nasdaq listed companies .5 billion cough and cold category.
Future events and actual results could differ materially from those set forth
in, contemplated by, or underlying the forward-looking statements. We do not undertake , and we
specifically disclaim, any obligation to publicly update or revise any
forward-looking statement whether as a result of new information, future
events or otherwise.

mucous remedy

BURBANK, Calif.

Regis
Monarch Beach Resort in Dana Point, California.52

PHOENIX, Matrixx Initiatives , Inc.0 million, a 48% increase above net sales of $18.52 per share, compared to net income for
2003 of $3. Additionally, in July 2004 Matrixx began
distributing six new Cough Mist(TM) products for the 2004-2005 cough/cold
season. The words "believe,"
"expect," "plan," "anticipate," and other similar statements of expectation
identify forward-looking statements and include statements regarding: (i) our
belief that significant growth opportunity continues to exist; (ii) our
expectations that the rate of net income growth may slow; (iii) our
expectations regarding levels of research and development, legal, and
marketing expenses in 2005; and (iv) our expectations regarding the
introduction of product improvements, new products, and a new brand in 2005.

unobstructed snore

The Company will be presenting at 1:00 p.)

2 million in the
fourth quarter of 2003. We continue to aggressively defend against these
claims.52 $0.zicam.

eez snorers

Information on the institute may be obtained by calling
818-842-1327 or by visiting http://www. To listen to the
live presentation please visit www.0 million, or $0.
Mr.17 $0.matrixxinc.

breathing tissues

Chronic cough, which may indicate Chronic Obstructive Pulmonary Disease
(COPD), includes several related conditions that limit the ability of an
individual to exhale. "Occasional coughing can be normal, but it can also be
a symptom of something more serious like asthma, acid reflux disease, post
nasal drip or even lung cancer.

Matrixx Initiatives Inc. to Present at the Roth Capital Partners 17th Annual Growth Stock Conference

For more information regarding Matrixx products, go
to www.

About the Roth Capital Partners 17th Annual Growth Stock
Conference

This conference will feature more than 220 leading growth
companies in sectors such as Technology, Healthcare, Financial
Services and Consumer Products . The average market cap of this
year's presenters is around $330 million, with the median around $185
million. The studies that have been conducted and reviewed by independent
medical experts and other evidence support our contention that these claims
are unfounded. We focused on product
cost reductions in 2004 and, on average, achieved a 4% cost reduction for each
unit sold compared to the prior year. 31, 2002
Cash and Marketable
Securities $12 ,694 $10,683 $12,010
Accounts Receivable --
Trade $12,386 $11,472 $7,038
Inventory $7,241 $3,268 $1,573
Restricted Cash $5,000 $0 $0
Total Assets $60,134 $50,077 $47,185
Current Liabilities $15,091 $11,287 $12,030
Working Capital $23,205 $17,580 $10,189
Total Debt $0 $0 $5,254
Shareholders' equity $44,126 $38,790 $35,155

About Matrixx Initiatives, Inc.

somni remedy

, The Institute for Better
Breathing (IBB) announced today the creation of Southern California's first
"Cough Center" designed to help people struggling with emphysema, chronic
bronchitis or other chronic coughs they just can't shake.instituteforbetterbreathing. A replay of the presentation will
be archived at the same web site address for 30 days.
Zicam, LLC, its wholly-owned subsidiary, produces, markets and sells
Zicam(R) Cold Remedy nasal gel, a patented, homeopathic remedy that
has been clinically proven to reduce the duration and severity of the
common cold.

mouthpiece airways

D.com.com, or Bill Barba, investor
relations, at 602-385-8881, bbarba@matrixxinc.2 Million and EPS Increased to $0. Johnson continued, "Our continued growth is a great testament to our
business model which allows us to rapidly introduce new, innovative products
that provide unique benefits to consumers. These insights into our user base encourage us to
continue to build brand awareness , focusing on trial generating devices and
increasing advertising support levels."
According to William Hemelt, Executive Vice President and Chief Financial
Officer, "We realized exceptional financial results in 2004. 31, 2004 Dec.

tissues snoring

Its offices are located in Burbank
and Glendale. Interested parties
should login 15 minutes prior to the event to register and to install
Windows Media Player if necessary. We now sell products in the cold
(3 nasal delivery products and 3 oral delivery products ), allergy/sinus
(4 nasal delivery products), and cough (6 oral delivery products) market
groups within the overall $3. In 2005, we expect to increase our level of investment in research and
development and will continue to invest in marketing efforts to sustain
revenue growth.com, or Bill
Barba , investor relations, at 602-385-8881, bbarba@matrixxinc.

cushion tissues

Roach, most causes of chronic cough can be effectively
treated once the cause is known. Factors
that could cause actual results to differ materially from the Company's
expectations include the severity of the next cold season, the possibility
that future sales of Zicam products will not be as strong as expected, the
possibility that supply issues may impact future sales of Zicam products, the
possibility that the Company's products may face increased competition or
negative publicity, the potential impact of current and future product
liability litigation, regulatory issues, or public relations challenges, the
possibility of delays or other difficulties in implementing new product
improvements and introducing to the marketplace new products and brands; and
the possibility that expenses, including legal expenses, may exceed budgeted
amounts.

breathe breathing

"A cough that persists for more than three weeks should be evaluated by a
physician who specializes in airway and breathing disorders," said James
Roach, M. "There really is no reason for someone to struggle with an ongoing
cough when the cause can be readily found and treatment instituted after
appropriate testing.com/2005%20DP%20Conference%20Web%20Site/
Roth%20DP ."
Mr. Increased legal expense continues
to put pressure on operating income. Other factors that could cause actual results to differ materially
from the Company's expectations are described in the Company's Annual Report
on Form 10-K filed in March 2004 and the Company's Quarterly Report on Form
10-Q filed in November 2004, under the heading "Risk Factors", both filed
pursuant to the Securities Exchange Act of 1934.

snore tissues

"
According to Dr.

Business Editors/Health/Medical Writers
Roth Capital Partners 17th Annual Growth Stock Conference

PHOENIX----Matrixx Initiatives , Inc.html?content=home (Due to its length, this URL may need to
be copied/pasted into your Internet browser's address field. We built inventory levels during the
year and have been able to meet increased demand during the cough and cold
season without any out of stock situations. is engaged in the development , manufacture and
marketing of over-the-counter (OTC) pharmaceuticals, which utilize innovative
drug delivery systems.

airway plugs

Southern California's First 'Cough Center' Opens at the Institute for Better Breathing

, a board-certified pulmonologist at the Burbank-based Institute
for Better Breathing . PT. Remove
the extra space if one exists.

Matrixx Initiatives Inc. Reports 48% Increase in Fourth Quarter Sales and EPS of $0.17

5 million.3 million, or $0.7 9.